Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
Enanta reported fiscal Q3 revenue of $14.4 million, a decline from $18.3 million in the prior year due to lower sales of AbbVie’s HCV regimen MAVYRET, while posting a net loss of $19.5 million or $0.67 per share. The company remains on track with its pipeline, initiating dosing in the LOTUS Phase 2b pediatric RSV trial and preparing to launch the RESOLVE registrational trial in high-risk adults in the fourth quarter. Management confirmed a strong balance sheet with $211.5 million in cash and marketable securities, which is expected to fund operations into fiscal 2029.
Key figures
- Revenue
- 14359000
- Revenue Yoy
- -21.6%
- Rd expenses
- 22100000
- Cash position
- 211500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.